...
首页> 外文期刊>Journal of drugs in dermatology: JDD >Imiquimod as an antiangiogenic agent.
【24h】

Imiquimod as an antiangiogenic agent.

机译:伊铵作为抗血管生成剂。

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Imiquimod (imidazoquinoline 5%) is a topical immune response modifier agent that inhibits angiogenesis, the growth of new blood vessels. In addition to its stimulation of cell-mediated immunity, imiquimod's antiangiogenic activity contributes to its clinical efficacy by interfering with pathological neovascularization that promotes disease progression. The antiangiogenic mechanisms of imiquimod are due to its: 1) induction of cytokines that themselves inhibit angiogenesis (interferons, IL-10, IL-12); 2) local up-regulation of endogenous angiogenesis inhibitors (TIMP, TSP-1); 3) local down-regulation of pro-angiogenic factors (bFGF, MMP-9); and 4) promotion of endothelial cell apoptosis. This report discusses these mechanisms and the rationale for imiquimod's use as an antiangiogenic agent. Key principles of antiangiogenic therapy are presented to describe how imiquimod may be applied in a well-tolerated fashion to treat a broad range of angiogenesis-dependent dermatological conditions, including actinic keratosis (AK), basal cell carcinoma (BCC), squamous cell carcinoma (SCC), lentigo maligna, hemangiomas, Kaposi's sarcoma, pyogenic granuloma, and external genital warts.
机译:咪嗪(咪唑喹啉5%)是一种局部免疫应答改性剂,其抑制血管生成,新血管的生长。除了刺激细胞介导的免疫之外,咪喹莫德的抗血管生成活性通过干扰促进疾病进展的病理新生血管而有助于其临床疗效。咪喹莫特的抗血管生成机制是:1)诱导细胞因子本身抑制血管生成(干扰素,IL-10,IL-12); 2)内源性血管生成抑制剂的局部上调(TIMP,TSP-1); 3)局部下调促血管生成因子(BFGF,MMP-9); 4)促进内皮细胞凋亡。本报告讨论了这些机制和咪喹莫德用作抗岩剂的理由。提出了抗血管生成治疗的关键原理以描述咪喹莫特如何以良好耐受的方式应用,以治疗广泛的血管生成依赖性皮肤病,包括光化角瘤(AK),基底细胞癌(BCC),鳞状细胞癌( SCC),Lentigo Maligna,Hemangiomas,Kaposi的肉瘤,脓菌肉芽肿和外部生殖器疣。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号